Oct282019UncategorizedCategory: UncategorizedBy Charlotte Maddalena28 October 2019 Author: Charlotte Maddalena Post navigationPreviousPrevious post:ORPHELIA announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development OfficerNextNext post:Preclinical data of novel ICI combination with anti-PD1 or anti-CTLA4 therapiesRelated PostsOrphelia Pharma secures US patent covering KIZFIZO®, first drinkable formulation of temozolomide29 November 2023ORPHELIA Pharma to support the European paediatric Soft Tissue Sarcoma Study Group winter meeting28 November 2023Medicines for Europe: 5th Value Added Medicines Conference, 7th November 2023, Brussels2 November 2023Event : BioEurope Fall 2023 – November 6-8, 2023; Munich, Germany30 October 2023Five new projects supported by our Foundation28 October 2023Orphelia Pharma files EU marketing authorization application for KIZFIZO®24 October 2023
Orphelia Pharma secures US patent covering KIZFIZO®, first drinkable formulation of temozolomide29 November 2023
ORPHELIA Pharma to support the European paediatric Soft Tissue Sarcoma Study Group winter meeting28 November 2023
Medicines for Europe: 5th Value Added Medicines Conference, 7th November 2023, Brussels2 November 2023
